Help
Subscribe


Submit Videos to GastroHep Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Predicting efficacy and safety of infliximab therapy in IBD

Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease, reports June's publication of the Alimentary Pharmacology & Therapeutics.

News image

Infliximab is a chimeric murine/human anti-TNF antibody (Ab) used for the treatment of Crohn's disease and ulcerative colitis.

Loss of response is common and associated with development of anti-Infliximab antibodies during ongoing therapy.

However, human anti-murine immunoglobulin antibodies are common and may cross-react with the murine part of Infliximab.

Dr Steenholdt and colleagues investigated whether antibodies binding to Infliximab's Fab region are present in IBD patients before exposure to Infliximab, and whether they predict efficacy and safety of Infliximab therapy.

The team performed an observational, retrospective cohort study of patients with Crohn's disease and ulcerative colitis.

The doctors noted that pre-treatment levels of Infliximab-Fab reactive IgG antibodies were significantly lower in Crohn's disease patients in remission after 1 year of maintenance Infliximab than in the rest of the patients, and lower than in patients with secondary loss of response in particular.

A cut-off of 439 mU infliximab-Fab reactive IgG Ab per litre comprised  patients with long-term remission
Alimentary Pharmacology & Therapeutics

A cut-off concentration of 439 mU infliximab-Fab reactive IgG antibody per litre comprised all patients who later obtained long-term sustained remission on Infliximab.

The researchers observed similar trends in ulcerative colitis.

The pre-treatment levels of Infliximab-Fab reactive IgG antibodies were markedly higher in patients developing infusion reactions to Infliximab than in the remaining patients.

Dr Steenholdt's team concluded, "Infliximab-Fab reactive IgG antibodies present in serum from IBD patients before infliximab therapy associate with lack of long-term efficacy and safety."

"Assessments of such antibodies may help clinicians to choose between treatment with infliximab and more humanized agents."

Aliment Pharmacol Ther 2013: 37(12): 117-1183
29 May 2013

Go to top of page Email this page Email this page to a colleague

 21 December 2014

Advanced search
 19 December 2014 
Idiopathic inflammatory demyelinating disease in IBD
 19 December 2014 
Colorectal cancer risk for first-degree relatives
 19 December 2014 
Thiopurine treatment and colectomy in ulcerative colitis
 18 December 2014 
Assessment of Crohn's disease activity
 18 December 2014 
Vitamin D and sustained virologic response in HCV
 18 December 2014 
Factor for treatment in IBS
 17 December 2014 
Non-invasive measures of fatty liver
 17 December 2014 
Remission from hepatic encephalopathy with rifaximin
 17 December 2014 
Colonic adenoma recurrence after endoscopic resection
 16 December 2014 
Screening esophagus during routine US
 16 December 2014 
Therapeutic targets in IBD
 16 December 2014 
Diagnostic tool for dysplasia in Barrett's
 15 December 2014 
Esophageal adenocarcinoma and Barrett's
 15 December 2014 
Outcomes of mildly abnormal liver function tests
 15 December 2014 
Food allergy and food intolerances
 12 December 2014 
Hospital readmission after colorectal resection
 12 December 2014 
Detecting intestingal damage in Crohn's
 12 December 2014 
SSRIs for noncardiac chest pain
 11 December 2014 
Hep C and post-liver transplant diabetes
 11 December 2014 
Antiviral therapy and post-hepatectomy survival
 11 December 2014 
Barrett’s risk factors in African Americans vs Non-Hispanic Whites
 10 December 2014 
Prompt endoscopy for uninvestigated dyspepsia
 10 December 2014 
Microbiota composition on gluten-free diet in celiac disease
 10 December 2014 
Utilization of health care resources in ileostomy patients
 09 December 2014 
Diverticular disease and irritable bowel syndrome
 09 December 2014 
Management of acute colonic diverticulitis
 09 December 2014 
Food intolerance
 08 December 2014 
Portal vein obstruction
 08 December 2014 
Readmission after restorative proctocolectomy with IPAA
 08 December 2014 
Metachronous colorectal cancer
 05 December 2014 
Esophageal cancer in Veterans with Barrett’s esophagus
 05 December 2014 
Clinical outcome in pediatric Crohn's
 05 December 2014 
Hepatocellular carcinoma surveillance survey
 04 December 2014 
Diagnosis of NAFLD and NASH
 04 December 2014 
Ethnic disparities in gastric cancer
 04 December 2014 
Gilbert's syndrome and respiratory health
 03 December 2014 
Unmet treatment needs of GERD
 03 December 2014 
Finding sessile serrated adenomas during colonoscopy
 03 December 2014 
Antibiotics in acute uncomplicated diverticulitis
 02 December 2014 
Vit D and sustained virologic response in Hep C
 02 December 2014 
Severe esophagitis and upper GI bleeding
 02 December 2014 
Critical illness in patients with IBD
 01 December 2014 
Algorithms for the diagnosis of Lynch syndrome
 01 December 2014 
Differentiates inflammatory from functional intestinal disorders
 01 December 2014 
Racial disparities in colorectal cancer survival
 28 November 2014 
C. diff and pediatric IBD
 28 November 2014 
Fruit and vegetable consumption and esophageal cancer
 28 November 2014 
IBD and students' adjustment to college
 27 November 2014 
Prediction of functional GI disorders later in life
 27 November 2014 
Differences in the incidence of esophageal adenocarcinoma
 27 November 2014 
End points of outcomes in primary biliary cirrhosis
 26 November 2014 
Detection of gastric precancerous conditions
 26 November 2014 
Vegetables and garlic and colorectal cancer risk
 26 November 2014 
Fertility in women with celiac disease
 25 November 2014 
Esophagogastric junction of children with GERD
 25 November 2014 
Symptom activity index for eosinophilic esophagitis
 25 November 2014 
Placebo response rate in fistulizing Crohn's
 24 November 2014 
Nasoenteric tube feeding in acute pancreatitis
 24 November 2014 
Corticosteroids and infections in elderly-onset IBD
 24 November 2014 
Adhesions in abdominal and pelvic surgery

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2014 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us